|
|
Cardinal Health Inc (CAH) |
|
Price: $82.8300
$-1.87 
-2.208%
|
| Day's High:
| $85.0205
| Week Perf:
| -3.66 %
|
| Day's Low: |
$ 82.60 |
30 Day Perf: |
0.91 % |
| Volume (M): |
1,936 |
52 Wk High: |
$ 87.03 |
| Volume (M$): |
$ 160,392 |
52 Wk Avg: |
$71.57 |
| Open: |
$84.70 |
52 Wk Low: |
$49.70 |
|
|
| Market Capitalization (Millions $) |
21,370 |
| Shares
Outstanding (Millions) |
258 |
| Employees |
46,500 |
| Revenues (TTM) (Millions $) |
198,662 |
| Net Income (TTM) (Millions $) |
465 |
| Cash Flow (TTM) (Millions $) |
1,634 |
| Capital Exp. (TTM) (Millions $) |
428 |
Cardinal Health Inc
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a holding company
encompassing a number of operating subsidiaries that do business as Cardinal Health.
The Company is a leading provider of products and services supporting the health
care industry, and helping health care providers and manufacturers improve the
efficiency and quality of health care.
Company Address: 7000 Cardinal Place Dublin 43017 OH
Company Phone Number: 757-5000 Stock Exchange / Ticker: NYSE CAH
| CAH is expected to report next financial results on August 10, 2023. |
Next quarterly dividend pay out on July 17, 2023. |
|
|
|
Customers Net Income fell by |
CAH's Customers Net Profit Margin fell to |
-5.62 % |
2.83 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Petmed Express Inc
Despite a recent slip into deficit, there is optimism in the stock market surrounding Petmed Express Inc., with the company's recent report highlighting strong sequential growth in revenue. While PETS may have posted a deficit of $-0.25 per share, this was an improvement from the $0.30 per share seen the previous year. And while revenue dipped -5.447% to $62.41 million, it experienced an impressive 6.008% increase sequentially from the previous period.
Looking ahead, the company's revenue for the fiscal period 2023 was an impressive $256.86 million, with a net income of $0.23 million. In addition, Petmed Express Inc. also reported that its EPS dropped, but this news must be taken in context as PETS's EPS had increased significantly in prior reporting periodsDespite the disappointing results from the last quarter, the Petmed Express Inc team is committed to returning the company to strong financial results. The August 2023 financial update promises to offer a clearer picture of the company's recent performance and future trajectory. Investors should remain optimistic as Petmed Express Inc continues to demonstrate a commitment to growth, innovation, and delivering value to its shareholders.
|
|
Can B Corp
Can B Corp?s financial results for the fiscal period ending March 31, 2023, present a mixed picture for the company. On the positive side, the company has improved its loss per share, going from $-1.10 a year before to $-0.36 per share. Additionally, its Income per Share has improved from $-0.68 per share from the prior financial reporting period.
However, the picture isn?t all bright, as the company has experienced a significant drop in revenue. Revenue has decreased by 49.508% to $0.94 million from $1.86 million in the comparable financial reporting period a year prior. This decrease in revenue is a cause for concern as it may indicate that Can B Corp is not doing as well as previously thought. Nevertheless, sequentially, the revenue grew by 41.021% from $0.67 million, which is an improvement.
|
|
Trees Corporation
Trees Corporation, a Pharmacy Services and Retail Drugstore company, has released its earnings report for the first quarter of the 2023 earnings season. Despite a surge in revenue, the company suffered from diminishing returns, expanding at a rate of $-0.02 per share. This comes as a disappointment considering the company?s revenue rose by 43.022% to $5.11 million from the previous year?s comparable quarter.
The first quarter?s results seem to follow a pattern from the preceding quarter. In the previous quarter, Trees Corporation saw a revenue of $3.46 million and $-0.06 per share. While the company saw an increase in revenue in the first quarter of the 2023 earnings season, the diminishing returns suggest that the company needs to reassess its operations to improve profitability.
|
|
Bimi International Medical Inc
Bimi International Medical Inc, a leading healthcare company, has recently reported a significant decrease in revenue and earnings in their first quarter financial report for 2023. In the corresponding financial reporting period a year prior, the company reported earnings of $0.06 per share, whereas in the first quarter of 2023, the company slipped into a loss of -$0.23 per share. Similarly, earnings per share plummeted from $6.39 to almost zero in the first quarter of 2023.
Moreover, the company saw a sharp decline in revenue, dropping by -76.791% to $3.20 million from $13.78 million in the corresponding financial reporting period a year prior. However, the good news is that the company did see an improvement in sequential revenue, turning positive from $-34,046.66 million.
|
|
Medavail Holdings Inc
The financial results for the first quarter of 2023 for Medavail Holdings Inc are not positive. The company lost $0.16 per share, which is an improvement from the previous year's loss of $0.40 per share, but still represents a deficit. This deficit also grew from the previous reporting period where the loss was only $0.09 per share. Additionally, the revenue for the first quarter of 2023 plummeted by 93.197% to just $0.62 million compared to $9.11 million a year ago. The drop was even more severe sequentially, with revenue tumbling by 94.537% from $11.35 million. Finally, the net deficit for the first quarter of 2023 was even larger than the previous year's, at $-17.330 million compared to $-13.022 million.
These financial results are a cause for concern for Medavail Holdings Inc as they show a significant decline in revenue. The drop in revenue is particularly concerning as it is so severe and is likely to have a ripple effect across other areas of the business. The increasing net deficit is also an indicator that the company is struggling to operate effectively, and the year-over-year loss per share suggests that they are not making progress in improving their financial situation.
|
| Per Share |
Current |
| Earnings (TTM) |
1.74 $ |
| Revenues (TTM) |
770.01 $
|
| Cash Flow (TTM) |
6.33 $ |
| Cash |
15.47 $
|
| Book Value |
-
|
| Dividend (TTM) |
1.97 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.74 $
|
| Revenues (TTM) |
770.01 $ |
| Cash Flow (TTM) |
6.33 $ |
| Cash |
15.47 $
|
| Book Value |
- |
| Dividend (TTM) |
1.97 $ |
|
|
| |
| Pharmaceutical |
|
Segment |
|
 |
of total Revenue |
| Medical |
|
Segment |
|
|
of total Revenue |
| Corporate |
|
Segment |
|
|
of total Revenue |
| |
|
|
1.7%